Xencor, Inc. develops engineered antibody therapeutics for cancer and autoimmune diseases using its XmAb technology platform and related antibody-engineering formats. News about XNCR commonly covers clinical and preclinical updates for XmAb drug candidates, including TL1A programs such as XmAb942 and XmAb412, T-cell engaging bispecific antibodies such as XmAb819 and XmAb541, and presentations of data at medical meetings.
Recurring company updates also include quarterly financial results, research-and-development priorities, collaboration and licensing activity, intellectual-property developments tied to Xtend Fc domain technology, and royalty matters involving partner-marketed medicines such as Ultomiris.
Xencor (XNCR) reported third-quarter 2026 revenue of $116.5 million, alongside a return to quarterly profit and updates across its clinical pipeline. Net income attributable to Xencor was $39.4 million, or $0.50 per diluted share, versus a $6.0 million loss a year earlier. Revenue rose from $21.0 million, while research and development expenses increased to $84.3 million from $54.4 million.
Cash, cash equivalents and marketable debt securities totaled $555.7 million at September 30. Xencor expects $480 million–$500 million at year-end and funding into 2029. XmAb819 produced a 45.5% confirmed response rate in 11 evaluable patients at the selected intravenous dose. Subject to regulatory feedback, Xencor plans a Phase 3 study by year-end 2027. Its XmAb942 ulcerative colitis study remains on track for primary endpoint analysis in the second half of 2027; initial XmAb412 healthy-participant data are planned for the first half.
Xencor (XNCR) selected 400 mcg/kg as the proposed intravenous Phase 3 dose for XmAb819 after updated Phase 1 kidney cancer results. At the October 1, 2026 data cut, 11 efficacy-evaluable patients at this dose had a 45.5% confirmed response rate and 55% response rate including an unconfirmed response. Estimated progression-free survival at six months was 82%; median progression-free survival was not reached.
Across the expansion-dose cohorts, 72.1% experienced Grade 3 or higher treatment-related adverse events, and 5.9% discontinued because of related treatment-emergent adverse events. Xencor plans FDA discussions about a potential accelerated approval pathway in selected previously treated patients in the first half of 2027, and potential registration-enabling development by the end of 2027. A planned randomized trial would compare XmAb819 with tivozanib in previously treated advanced clear cell renal cell carcinoma.
Xencor (XNCR) will host an October 26 webcast to discuss Phase 1 results for XmAb819 in advanced clear cell renal cell carcinoma.
The webcast begins at 7:00 a.m. EDT, following an October 25 oral presentation at the ESMO Congress 2026 in Madrid. Xencor plans to initiate a registration-enabling study in 2027 of XmAb819 as a standalone treatment in advanced clear cell renal cell carcinoma. Expansion cohorts are evaluating intravenous doses to support dose selection for the planned Phase 3 study, while dose escalation for injections under the skin continues. Two additional sub-studies opened enrollment in the second and third quarters of 2026.
Xencor (XNCR) will present at the Cantor Global Healthcare Conference on Wednesday, September 9, 2026, at 10:55 a.m. EDT / 7:55 a.m. PDT.
A live webcast will be accessible via the Investors section of Xencor’s website under “Events & Presentations,” with a replay available for at least 30 days.
Xencor (NASDAQ:XNCR) reported second quarter 2026 revenue of $51.2 million, up from $43.6 million a year earlier, and a net loss of $21.7 million (vs. $30.8 million). Cash, cash equivalents and marketable debt securities were $486.4 million at June 30, 2026.
The company recorded $27.6 million of Ultomiris U.S. royalty revenue after a $105 million settlement with Alexion, with the remaining $77.4 million to be recognized in Q3 2026. Xencor also received a $10 million milestone from Zenas after a BLA filing for obexelimab.
R&D expense rose to $71.9 million and G&A to $16.4 million. Xencor expects to end 2026 with $420–$440 million in cash and to fund operations through 2028. The update highlighted progress in multiple clinical programs, including XmAb819, XmAb541, XmAb942, XmAb412, plamotamab and XmAb657, plus Fast Track designation for XmAb541 and upcoming data milestones.
Xencor (NASDAQ: XNCR) agreed a Settlement Agreement with Alexion Pharma International Operations to resolve a commercial dispute over U.S. royalties on Ultomiris. Xencor will receive $105 million in two equal payments of $52.5 million, the first expected in August 2026 and the second on the one-year anniversary of the executed agreement. In return, Alexion will have no further obligation to pay royalties on U.S. sales of Ultomiris.
According to Xencor, royalties on ex-U.S. sales of Ultomiris are expected to continue under the existing license terms. Xencor stated that this resolution restores its operating cash runway estimate through 2028 and that, based on current operating plans, it expects to have sufficient cash resources to fund research, development and operations through 2028. Updated guidance for year-end 2026 cash, cash equivalents and marketable debt securities will be provided with second-quarter 2026 financial results.
Xencor (NASDAQ:XNCR) announced that Phase 1 clinical results for XmAb819, an ENPP3 x CD3 T‑cell engaging bispecific antibody, in advanced clear cell renal cell carcinoma (ccRCC) have been accepted for a proffered paper oral presentation at the ESMO Congress 2026, held October 23‑27 in Madrid, Spain. The talk will highlight expansion‑cohort data from intravenous dosing used to inform a recommended Phase 3 dose, with a pivotal monotherapy study in advanced ccRCC planned to begin in 2027.
According to Xencor, the Phase 1 trial (NCT05433142) is evaluating XmAb819 across ENPP3+ tumors. Ongoing work includes IV expansion cohorts in advanced ccRCC, subcutaneous dose escalation in ccRCC, a sub‑study in ENPP3+ advanced colorectal, non‑small cell lung and papillary renal cancers opened in Q2 2026, and a planned sub‑study in intermediate‑ or poor‑risk advanced ccRCC after IO doublet therapy set to open in Q3 2026. ESMO indicated the abstract will be available online at 3:05 p.m. PDT on October 18, 2026.
MindWalk Holdings (NASDAQ: HYFT) reported that over 20 drug candidates in partner pipelines originated from its antibody discovery work, with 10 programs now in active Phase 1–3 clinical trials across oncology, immunology, neurology, and infectious disease.
The company highlighted its HYFT® and LensAI™ biological intelligence infrastructure, built on a Knowledge Graph indexing 660 million biological patterns and 25 billion relationships, and a record of 400+ peer-reviewed publications and patents supporting collaborations with firms such as Annexon, argenx, Xencor, Cullinan Oncology, and others.
Xencor (NASDAQ:XNCR) reported Q1 2026 results and pipeline progress on May 6, 2026. Cash, cash equivalents and marketable securities were $541.8M at March 31, 2026; company expects $380M–$400M year-end 2026 and funding into mid‑2028. Q1 revenue was $4.5M (includes a $6.6M one‑time royalty reduction); Q1 net loss was $128.9M or $(1.71) per share. Key clinical milestones: XmAb819 expansion cohort data due 2H26; XmAb412 first‑in‑human planned 3Q26; XENITH‑UC blinded interim analysis expected around year‑end 2026.
Xencor (NASDAQ:XNCR) presented Phase 1 final results for XmAb942 and preclinical data for XmAb412 at DDW and will host a webcast on May 5 at 8:00 a.m. EDT. XmAb942 showed a 74.1-day terminal half-life, supports a single subcutaneous 12-week maintenance dose, and informs a ~220-patient Phase 2b XENITH-UC study with a blinded interim around year-end 2026 and primary endpoint readout in H2 2027. XmAb412 (TL1A x IL23p19) is planned to enter first-in-human healthy-participant dosing in 3Q26; predicted human half-life 60–70 days and single-/sub-picomolar affinities were reported.